Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 08:30 ET
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences
September 21, 2023 16:05 ET
|
Tenaya Therapeutics, Inc.
TN-301 First-in-Human Phase 1 Clinical Trial Results and Preclinical Combination Data to be Presented at Heart Failure Society of America Annual Scientific Meeting TN-201 Interim Seroprevalence Study...
Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina
August 16, 2023 08:00 ET
|
Imbria Pharmaceuticals Inc.
– IMPROVE-ISCHEMIA, a randomized, placebo-controlled trial, with topline data expected in 4Q 2023 – – Additional Phase 2 data read-outs expected in 4Q 2023, including topline from the IMPROVE-HCM...
Worldwide Precision Cardiology Industry to 2027 - by Offering, Sample Type, Technology, Application, End-user and Region
October 26, 2022 07:48 ET
|
Research and Markets
Dublin, Oct. 26, 2022 (GLOBE NEWSWIRE) -- The "Global Precision Cardiology Market: Competition Forecast and Opportunities to 2027" report has been added to ResearchAndMarkets.com's offering.The...
Global Precision Cardiology Industry 2021-2031: Focus on Offering, Sample, Technology, Application, End-user, and Region
February 28, 2022 06:28 ET
|
Research and Markets
Dublin, Feb. 28, 2022 (GLOBE NEWSWIRE) -- The "Precision Cardiology Market - A Global and Regional Analysis: Focus on Offering, Sample, Technology, Application, End User, and Region - Analysis and...
Healthtech Solutions, Inc. (HLTT), Parent Company of Cutting-Edge Medical Technology Companies, Files Reg A With SEC
March 17, 2021 08:30 ET
|
Healthtech Solutions, Inc.
March 8, 2021, filing to raise up to $75 million. Maximum of 1,500,000 shares of Series B preferred stock offered at price of $50 per share.Healthtech Solutions, Inc. is organized to pursue...
Cardiomyopathy Medication Market To Reach USD 1,148.9 Million By 2026 | Reports And Data
November 04, 2019 12:11 ET
|
Reports and Data
New York, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Rising prevalence of cardiomyopathy diseases, new product development for targeted cardiac illnesses, collaborations for medical advancements and...
MyoKardia Announces Abstracts Selected for Presentation at the American Heart Association Scientific Sessions 2019
November 04, 2019 08:30 ET
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced the presentation of several abstracts at the upcoming American Heart Association (AHA)...
MyoKardia Launches 2nd Annual MyoSeeds™ Research Grants Program to Advance Independent Research in Heart Disease
August 15, 2019 08:30 ET
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 15, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. today announced the launch of the 2nd Annual MyoSeeds™ Research Grants Program, an initiative to support original,...